Stock Trading Tools for Success ✌️【Work Experience】✌️Low-risk, high-reward investments starting from ₹500. Begin today! Stock Trading Tools for Success - AI-Driven Investments for Stability ✌️【Work Experience】✌️Invest ₹500 and let your wealth grow with our proven, secure strategies!

Stock Trading Tools for Success ✌️【Work Experience】✌️Low-risk, high-reward investments starting from ₹500. Begin today!Pharmaceutical giant Dr Reddy’s Laboratories (DRL) saw its shares surge 4.34% on Thursday in an otherwise sluggish market, reaching an intraday high of Rs 1,330.45 following an upgrade by Nomura.The Tokyo-based brokerage has upgraded the stock from ‘Neutral’ to ‘Buy’ with a revised target price of Rs 1,500, down from Rs 6,499, factoring in the 1:5 stock split on October 28.“We assess that risk-reward is favourable and thus upgrade the stock to Buy (from Neutral).

Stock Trading Tools for Success ✌️【Work Experience】✌️Achieve financial freedom with ₹500. Invest smart and earn fast!We reduce FY25/26F earnings by 13%/14% to factor in higher overhead costs.

Note that changes to our earnings estimates and target price are due to DRL’s 1:5 stock split,” said Saion Mukherjee and AmlanJyotiDas, research analysts at Nomura.They also said the relative underperformance of the stock suggests that concerns about the high contribution of generic cancer drug gRevlimid are already priced in.

“We think the Street is concerned about the higher contribution from gRevlimid, which could start declining in FY26F.

Further, the overheads have increased significantly in the recent past.

In the first half of FY25, R&D/SG&A were higher by 29%/27% year-on-year.”While the stock has underperformed theNifty PharmaIndex over the past five years, the upgrade reflects Nomura’s confidence in Dr Reddy’s ability to overcome near-term challenges and capitalise on future opportunities.

Stock Trading Tools for Success ✌️【Work Experience】✌️Smart investments start with ₹500. Grow your wealth with minimal risk!The stock has risen only 13% over the past year, compared to the Nifty Pharma Index’s 36% growth.

Stock Trading Tools for Success ✌️【Work Experience】✌️Start with ₹500 and maximize your monthly earnings with high-yield investments.The underperformance persists despite a 22.Stock Trading Tools for Success Discover Part-Time Freelance Opportunities